Pregabablin Open-Label, Follow-On Safety Trial In Patients With Refractory Partial Epilepsy.

Purpose:

To evaluate the long-term safety of pregabalin in refractory partial epilepsy.

Criteria:

Inclusion Criteria: - Must have met the inclusion criteria for preceding double-blind study. - Have received double-blind study medication and wish to receive open-label pregabalin. Exclusion Criteria: - Pregnant or considering becoming pregnant. - Receiving any concomitant medication that could alter the effectiveness of their medication response or seizure frequency.

NCT ID:

NCT00141414

Primary Contact:

Study Director
Pfizer CT.gov Call Center
Pfizer

Backup Contact:

N/A

Location Contact:

Stanford, California 94305
United States



There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: November 18, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.